Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.

Pretreatment with desethyl KBT-3022 0.1, 0.3 and 1 mg/kg, i.v. prolongs the time required to achieve thrombotic occlusion in the femoral artery and inhibits collagen-induced platelet aggregation in whole blood ex vivo, each in a dose-dependent manner. Desethyl KBT-3022 inhibits the thrombin-induced aggregation of washed platelets in a concentration-dependent manner 1-40 μM[1].

[1]. Shimazawa M, et al. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. Eur J Pharmacol. 1997 Jun 11;328(2-3):183-9.

特别提醒：                                                                                                              

1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗，食品及化妆品等用途。请勿存放于普通住宅区。

2. 为了您的安全和健康，请穿好实验服并佩戴一次性手套和口罩操作。